Literature DB >> 27931609

Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension.

Tufik R Assad1, Anna R Hemnes2, Emma K Larkin2, Andrew M Glazer3, Meng Xu4, Quinn S Wells5, Eric H Farber-Eger6, Quanhu Sheng7, Yu Shyr8, Frank E Harrell4, John H Newman2, Evan L Brittain5.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is a common and morbid complication of left heart disease with 2 subtypes: isolated post-capillary pulmonary hypertension (Ipc-PH) and combined post-capillary and pre-capillary pulmonary hypertension (Cpc-PH). Little is known about the clinical or physiological characteristics that distinguish these 2 subphenotypes or if Cpc-PH shares molecular similarities to pulmonary arterial hypertension (PAH).
OBJECTIVES: The goal of this study was to test the hypothesis that the hemodynamic and genetic profile of Cpc-PH would more closely resemble PAH than Ipc-PH.
METHODS: Vanderbilt University's electronic medical record linked to a DNA biorepository was used to extract demographic characteristics, clinical data, invasive hemodynamic data, echocardiography, and vital status for all patients referred for right heart catheterization between 1998 and 2014. Shared genetic variants between PAH and Cpc-PH compared with Ipc-PH were identified by using pre-existing single-nucleotide polymorphism data.
RESULTS: A total of 2,817 patients with PH (13% Cpc-PH, 52% Ipc-PH, and 20% PAH) were identified. Patients with Cpc-PH were on average 6 years younger, with more severe pulmonary vascular disease than patients with Ipc-PH, despite similar comorbidities and prevalence, severity, and chronicity of left heart disease. After adjusting for relevant covariates, the risk of death was similar between the Cpc-PH and Ipc-PH groups (hazard ratio: 1.14; 95% confidence interval: 0.96 to 1.35; p = 0.15) when defined according to diastolic pressure gradient. We identified 75 shared exonic single-nucleotide polymorphisms between Cpc-PH and PAH enriched in pathways involving cell structure, extracellular matrix, and immune function. These genes are expressed, on average, 32% higher in lungs relative to other tissues.
CONCLUSIONS: Patients with Cpc-PH develop pulmonary vascular disease similar to patients with PAH, despite younger age and similar prevalence of obesity, diabetes mellitus, and left heart disease compared with patients with Ipc-PH. An exploratory genetic analysis in Cpc-PH identified genes and biological pathways in the lung known to contribute to PAH pathophysiology, suggesting that Cpc-PH may be a distinct and highly morbid PH subphenotype. Copyright Â
© 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diastolic pressure gradient; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; isolated post-capillary pulmonary hypertension; pulmonary arterial hypertension

Mesh:

Substances:

Year:  2016        PMID: 27931609      PMCID: PMC5157701          DOI: 10.1016/j.jacc.2016.09.942

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  43 in total

1.  Diastolic Pressure Gradient Predicts Outcome in Patients With Heart Failure and Preserved Ejection Fraction.

Authors:  Caroline Zotter-Tufaro; Franz Duca; Andreas A Kammerlander; Benedikt Koell; Stefan Aschauer; Daniel Dalos; Julia Mascherbauer; Diana Bonderman
Journal:  J Am Coll Cardiol       Date:  2015-09-15       Impact factor: 24.094

Review 2.  Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases.

Authors:  Jocelyn Dupuis; Marco Guazzi
Journal:  Can J Cardiol       Date:  2014-10-14       Impact factor: 5.223

3.  How to define pulmonary hypertension due to left heart disease.

Authors:  Mario Gerges; Christian Gerges; Irene M Lang
Journal:  Eur Respir J       Date:  2016-05-12       Impact factor: 16.671

4.  The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease.

Authors:  Emmanouil Tampakakis; Peter J Leary; Van N Selby; Teresa De Marco; Thomas P Cappola; G Michael Felker; Stuart D Russell; Edward K Kasper; Ryan J Tedford
Journal:  JACC Heart Fail       Date:  2014-11-12       Impact factor: 12.035

Review 5.  Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.

Authors:  James West
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

6.  Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension.

Authors:  Glenn Marsboom; Peter T Toth; John J Ryan; Zhigang Hong; Xichen Wu; Yong-Hu Fang; Thenappan Thenappan; Lin Piao; Hannah J Zhang; Jennifer Pogoriler; Yimei Chen; Erik Morrow; E Kenneth Weir; Jalees Rehman; Stephen L Archer
Journal:  Circ Res       Date:  2012-04-17       Impact factor: 17.367

7.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

8.  Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.

Authors:  Christian F Opitz; Marius M Hoeper; J Simon R Gibbs; Harald Kaemmerer; Joanna Pepke-Zaba; J Gerry Coghlan; Laura Scelsi; Michele D'Alto; Karen M Olsson; Silvia Ulrich; Werner Scholtz; Uwe Schulz; Ekkehard Grünig; Carmine D Vizza; Gerd Staehler; Leonhard Bruch; Doerte Huscher; David Pittrow; Stephan Rosenkranz
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

9.  Extraction of echocardiographic data from the electronic medical record is a rapid and efficient method for study of cardiac structure and function.

Authors:  Quinn S Wells; Eric Farber-Eger; Dana C Crawford
Journal:  J Clin Bioinforma       Date:  2014-09-20

10.  WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013.

Authors:  Jing Wang; Dexter Duncan; Zhiao Shi; Bing Zhang
Journal:  Nucleic Acids Res       Date:  2013-05-23       Impact factor: 16.971

View more
  66 in total

Review 1.  Pulmonary Hypertension Due to Left Heart Disease: an Update.

Authors:  Mandar A Aras; Mitchell A Psotka; Teresa De Marco
Journal:  Curr Cardiol Rep       Date:  2019-05-27       Impact factor: 2.931

2.  Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.

Authors:  Barry A Borlaug; Masaru Obokata
Journal:  Eur Heart J       Date:  2017-10-07       Impact factor: 29.983

3.  Reply to Voelkel and Newman: The Light at the End of the Long Pulmonary Hypertension Tunnel Brightens.

Authors:  Jason M Elinoff; Marc Humbert; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-09-15       Impact factor: 21.405

4.  Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study.

Authors:  Evan L Brittain; Meredith S Duncan; Joyce Chang; Olga V Patterson; Scott L DuVall; Cynthia A Brandt; Kaku A So-Armah; Matthew Goetz; Kathleen Akgun; Kristina Crothers; Courtney Zola; Joon Kim; Cynthia Gibert; Margaret Pisani; Alison Morris; Priscilla Hsue; Hilary A Tindle; Amy Justice; Matthew Freiberg
Journal:  Am J Respir Crit Care Med       Date:  2018-04-01       Impact factor: 21.405

5.  Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.

Authors:  Thomas M Gorter; Masaru Obokata; Yogesh N V Reddy; Vojtech Melenovsky; Barry A Borlaug
Journal:  Eur Heart J       Date:  2018-08-07       Impact factor: 29.983

6.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

7.  Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis.

Authors:  Sergio Caravita; Céline Dewachter; Davide Soranna; Sandy Carolino D'Araujo; Amina Khaldi; Antonella Zambon; Gianfranco Parati; Antoine Bondue; Jean-Luc Vachiéry
Journal:  Eur Respir J       Date:  2018-04-04       Impact factor: 16.671

8.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

9.  Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rebecca R Vanderpool; Melissa Saul; Mehdi Nouraie; Mark T Gladwin; Marc A Simon
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

10.  Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice: Implications for Pulmonary Hypertension Classification.

Authors:  Anna R Hemnes; Alexander R Opotowsky; Tufik R Assad; Meng Xu; Laura N Doss; Eric Farber-Eger; Quinn S Wells; Evan L Brittain
Journal:  Chest       Date:  2018-08-24       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.